Study Finds Generex Biotechnology Corporation Oral-lyn(TM) is Safe, Effective, May Reduce Complications of Insulin-Dependent Diabetes

WORCESTER, Mass., Dec. 3, 2009 (GLOBE NEWSWIRE) -- Published in the journal Diabetes, Obesity and Metabolism, an independent review of clinical trials of Generex Oral-lyn(TM) shows that the oral insulin spray has a faster onset of action and shorter duration of action than insulin delivered subcutaneously.
MORE ON THIS TOPIC